In Brain News, Brain Tumour Data, Research News

Glioblastoma (GBM) poses a significant challenge in treatment due to the difficulty in distinguishing true progression (TP) from pseudoprogression (PP) during chemoradiotherapy. TP signifies tumour growth with poor treatment response, while PP is characterized by tumour necrosis with a favourable response to treatment. This ambiguity makes it crucial to identify predictive markers early in the treatment process. A recent study delves into the world of delta radiomics, exploring their potential as prognostic indicators during MR-Linac radiotherapy for GBM.

What were the methods?

The study focused on a cohort of GBM patients undergoing 30 fractions of chemoRT on an MR-Linac.

MR-Linac integrates an MRI scanner with a linear accelerator. The linear accelerator is the machine that delivers high-energy radiation to the tumour. By combining it with an MRI, doctors can see detailed images of the tumour and surrounding anatomy in real-time, both before and during the radiation treatment. This enables them to make adjustments to the treatment plan based on the current position and shape of the tumour.

Two regions of interest were identified on daily treatment scans: the tumour and the post-surgical resection cavity. Patient responses were retrospectively classified as no progression (NP), TP, or PP.

Pseudoprogression has been a consistent clinical problem when monitoring brain tumours after people have received chemotherapy and radiotherapy. It occurs when imaging tests suggest the size of the tumour has increased, but the cancer hasn’t actually spread or grown, sometimes leading to unfortunate interference with patient care and the interpretation of brain scans.

The main cause of this phenomenon is the anti-cancer chemotherapy drug, Temozolomide, which is a part of the standard care for treatment of Glioma. The drug may cause an initial increase in the size of the tumour, followed by a decrease in tumour burden. Ultimately, this sometimes leads to a premature decision to discontinue the drugs which may actually be benefitting the individual.

What were the results?

Out of 36 screened patients, 27 were included in the study. Ten had NP, 11 had TP, and 6 had PP. The study employed a machine learning model, revealing that six of the ten indicated early changes in the lesion/tumour microenvironment.

Conclusion from the study

The study demonstrates that delta radiomic features extracted from MR-Linac imaging hold promise in predicting the differentiation between PP and TP in GBM patients during treatment.

This early identification, especially within the first 10 fractions, could empower physicians to adapt or intensify treatment in real-time for patients with poor responses. The findings pave the way for future research with larger patient cohorts and additional MRI contrasts, such as MR-Linac multiparametric MRI, to further enhance predictive capabilities.

To summarise, this research explores a new way of looking at brain tumour images during treatment. The study suggests that certain features, when analysed using advanced imaging techniques, can help doctors identify whether the tumour is responding well to treatment or not. This early detection could enable doctors to adjust the treatment plan in real-time for better outcomes. While more research is needed, this approach shows promise in improving the way we manage and treat glioblastoma.

To read more scientific information, click here.

Want to receive all the latest research straight to your inbox?

Sign-up our curated, jargon-free weekly research newsletter. Click here to fill out our contact form and select ‘research’ to opt into our research newsletter.

Get involved with research…

If you would like to use your experience and insight to support clinical research, consider signing up to be a PRIME advocate for brainstrust.

If you or someone you love is living with a brain tumour and have any questions around this latest news, or want to access support, give us a call on 01983 292 405 or email hello@brainstrust.org.uk. You can also visit our little brainstrust website which features support for children affected by brain tumour.

, ,
2024 RideLondon – Essex 100Events, Fundraising Events, Past Events
Promising Results in Recurrent Medulloblastoma with Innovative Treatment ApproachBrain News, Brain Tumour Data, Research News

Introduction

The Brain Tumour Data Dashboard lets you explore up -to-date, population level data about the brain tumours diagnosed in England between 2013 and 2015. Using the drop down menus on the left you can select different groups of patients to view in the charts below. In these charts the number of patients for every 100 diagnoses is displayed as images of people. Patients have been grouped by date of diagnosis, type of tumour, age, gender, and region in England.

For each group of patients you can explore the different routes to diagnosis, the proportion of those who received chemotherapy or radiotherapy, as well as the survival of the patients within each group. For more information about what these metrics mean please see the glossary.

How to use

  1. Select the year of diagnosis using the drop down menu.
  2. Select your patient group of interest from the four drop down menus in the following order:
    1. Tumour group
    2. Age at diagnosis
    3. Region of England
    4. Gender of patient
  3. To view a second chart to compare different groups of patients, click the ‘compare’ button.The second chart will appear below the first chart.

*Note that the tool is best used on a laptop or tablet rather than a mobile phone*

Unavailable data

Some of the data in these charts is not available.There are two main reasons for this:

  1. How the data has been grouped

If you cannot select a patient group from the drop down menus, the data is unavailable because of how the data has been organised.

Public Health England has grouped the data like a branching tree. The bottom of the tree contains all the patients with brain tumours, and then each branch divides the data by a certain characteristics, like age, or location of tumour. But the data is divided in an order, starting with location of the tumour (endocrine or brain), then by age, region, and gender. Age is at the start because it makes a bigger difference to survival rates and treatment rates than gender or region. Sometimes, after the data has been split by type of tumour and age, there is not enough data to be split again. This is because to protect patient confidentiality groups cannot contain less than 100 patients. Because some groups cannot be split further, you cannot create ‘totals’ for everyone by region or gender. For example, you cannot see results for all ages by region, or all brain tumours by gender. If these totals were calculated and released, it might be possible to identify patients, which is why Public Health England cannot release this data.

  1. Statistical reasons and data availability

If you can select a patient group from the chart menus, but the chart does not display, the data is unavailable for one of several reasons:

  1. Data is not yet available for the selected year from Public Health England.
  2. Data is not available because the data quality is too poor to release this statistic.
  3. Data is not available as the statistic is not appropriate for this group.
  4. Data is not available because the standard error of the estimate was greater than 20% and so the estimate has been supressed.

Up to date brain tumour data

Brain tumour data may influence the decisions you make about your care. Data also helps you understand the bigger picture, or landscape, in which you find yourself.

Brain tumour data and statistics influence the focus, and work of organisations like brainstrust. The information helps us to understand the scale and impact of the problems we are setting out to solve.

This tool helps you understand the landscape in which you find yourself having been diagnosed with a brain tumour. This landscape can be particularly tricky to navigate as there are many different types of brain tumour, all of which have a different impact.

The information you see represents the most up-to-date, official, population level brain tumour data available for England. Over time we will be adding to the brain tumour data available and publishing reports, with recommendations, as a result of what we learn from this data.

The data behind this content has come from Public Health England’s National Cancer Registration and Analysis Service (NCRAS) and is a direct result of the ‘Get Data Out’ project.

This project provides anonymised population level brain tumour data for public use in the form of standard output tables, accessible here: http://cancerdata.nhs.uk/standardoutput

Incidence

The number or rate (per head of population) of new cases of a disease diagnosed in a given population during a specified time period (usually a calendar year). The crude rate is the total number of cases divided by the mid-year population, usually expressed per 100,000 population.

Malignant

Malignant tumours which grow by invasion into surrounding tissues and have the ability to metastasise to distant sites

Mortality

The number or rate (per head of population) of deaths in a given population during a specified time period (usually a calendar year). The crude rate is the total number of deaths divided by the mid-year population, usually expressed per 100,000 population.

Non-malignant

Not cancerous. Non-malignant tumours may grow larger but do not spread to other parts of the body.

Survival

The length of time from the date of diagnosis for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the survival is one way to see how well a new treatment works. Also called ‘overall survival’ or ‘OS’.

Routes to Diagnosis

Under the ‘Routes to Diagnosis’ tab in the Brain Tumour Data Dashboard, you can explore the ways patients have been diagnosed with brain tumours. There are many ways, or routes, for cancers to be diagnosed in the NHS. A ‘route to diagnosis’ is the series of events between a patient and the healthcare system that leads to a diagnosis of cancer. The routes include:

  1. Two Week Wait

Patients are urgently referred by their GP for suspected cancer via the Two Week Wait system and are seen by a specialist within 2 weeks where they are diagnosed.

  1. GP referral

Diagnosis via a GP referral includes routine and urgent referrals where the patient was not referred under the Two Week Wait system.

  1. Emergency Presentation

Cancers can be diagnosed via emergency situations such as via A&E, emergency GP referral, emergency transfer or emergency admission.

  1. Outpatient

Outpatient cancer diagnoses include diagnoses via an elective route which started with an outpatient appointment that is either a self-referral or consultant to consultant referral. (It does not include those under the Two Week Wait referral system).

  1. Inpatient elective

Diagnosis via an inpatient elective route is where diagnosis occurs after the patient has been admitted into secondary care from a waiting list, or where the admission is booked or planned.

  1. Death Certificate Only

Diagnoses made by Death Certificate Only are made where there is no more information about the cancer diagnosis other than the cancer related death notifications. The date of diagnosis is the same as that of the date of death.

  1. Unknown

For some patients with a cancer diagnosis, there is no relevant data available to understand the route to diagnosis.

 

More information

If any of the statistical terms in this section of the brainstrust website are hard to understand, we recommend looking them up here:

Cancer Research UK’s Cancer Statistics Explained

http://www.cancerresearchuk.org/health-professional/cancer-statistics/cancer-stats-explained/statistics-terminology-explained#heading-Seven

If you are looking for help understanding terms relating specifically to brain tumours, and treatment, then the brainstrust glossary is available here:

https://www.brainstrust.org.uk/advice-glossary.php